HDAC-IN-9

HDAC-IN-9 (compound 4s) shows anti-proliferative activity (IC₅₀s of 1.821, 2.538, 4.84, 1.782, 2.525, 0.371 µM for MCF-7, MGC-803, HeLa, A549, HepG2, U937 cells, respectively)^[1].
HDAC-IN-9 displays 6.1, 3.2 and 4.6-fold selectivity ratios for 293 T, macrophages, and L02 cells respectively (IC₅₀s of 10.89, 5.63, 8.14 µM for 293 T, macrophages, and L02 cells, respectively)^[1].
HDAC-IN-9 shows inhibition activities against HDAC isoforms (IC₅₀s of 6.8, 0.06, 0.12, 8.5 µM for HDAC 1, HDAC 2, HDAC 6, HDAC 10, respectively)^[1].
HDAC-IN-9 (1, 2, 4 µM; 72 h; A459 cells) induces cell cycle arrest at the G2/M phase in a concentration-dependent manner^[1].
HDAC-IN-9 (1, 2, 4 µM; 72 h) induces apoptosis via a Caspase-dependent intrinsic mitochondrial-mediated pathway in A549 cells^[1].
HDAC-IN-9 (0, 0.5, 1, 2 µM; 48 h) shows anti-proliferative activity by the inhibition of angiogenesis and the reduction of endothelial cell metastasis in A549 cells^[1].
HDAC-IN-9 (0, 1, 2, 4 µM, 48 h) inhibits the invasion and migration of A549 cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.